港股收评：恒指涨0.86%、科指涨1.74%，科技及半导体股走高，黄金及风电板块集体回落

Market Performance - The Hong Kong stock market showed a positive trend on December 30, with the Hang Seng Index rising by 0.86% to 25,854.6 points, the Hang Seng Tech Index increasing by 1.74% to 5,578.38 points, and the National Enterprises Index up by 1.12% to 8,991.02 points [1] - Major technology stocks experienced gains, with Alibaba up by 0.84%, Tencent Holdings by 0.59%, JD Group by 1.43%, Xiaomi by 2.02%, NetEase by 2.59%, Meituan by 0.1%, Kuaishou by 1.1%, and Bilibili by 0.68% [1] - Semiconductor stocks also saw an increase, with InnoCare rising over 15%, SMIC up over 4%, and Hua Hong Semiconductor increasing nearly 4% [1] - The gold sector faced declines, with Zhu Feng Gold dropping over 6% and Lao Pu Gold down over 5% [1] - The "three oil giants" saw gains, with CNOOC rising nearly 4% [1] - Wind power stocks declined, with leading company Goldwind Technology falling nearly 11% [1] Corporate News - China Energy Construction (03996.HK) announced that its subsidiary won a bid for an ecological comprehensive governance project in Shaanxi Province, with a total contract value of 6.864 billion RMB, covering various construction aspects with a total duration of 36 months [2] - China Shenhua (01088.HK) reported that its second phase of the Qingyuan power plant's Unit 3 has completed a 168-hour trial run and is now in commercial operation, while Unit 4 is on track for commissioning in February 2026 [2] - Bay Area Development (00737.HK) signed a construction contract with Poly Longda for a total price of 775 million RMB [3] - China Railway Construction (01186.HK) completed the issuance of 4.45 billion RMB in corporate bonds [4] - Sichuan Energy Investment Development (01713.HK) entered into a strategic cooperation agreement with Mengsheng Electronics to deepen collaboration in the power industry [5] - China Supply Chain Industry (03708.HK) signed a "Test Version Data Center Agreement" with Shuwi Technology [6] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for its GLP-1/GIP receptor dual agonist injection in China [6] - Hutchison China MediTech (00013.HK) announced that its application for the new drug listing of HMPL-453 for second-line treatment of intrahepatic cholangiocarcinoma has been accepted and prioritized for review [6] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase I clinical study of HLX37 for advanced/metastatic solid tumors in China [6] - Henxin Technology (01085.HK) announced that its planned 350MW solar thermal power station is ready to commence construction [7] - Runhua Services (02455.HK) expanded its property management services to multiple provinces in western China [8] - Hong Kong International Industries (00480.HK) plans to sell its entire issued share capital of Yue Shan Limited for 452 million HKD [9] - Yimei International Holdings (01870.HK) received formal approval for its 218MW/436MWh electrochemical independent energy storage project in Shaoguan City [9] Institutional Insights - Huatai Securities noted that the volatility of asset performance and frequent style and industry rotations have led to a decrease in clarity regarding market themes, with two main consensus points: solid logic for bulk commodity sectors and a left-side bias in consumer sector allocations due to weak domestic recovery [10] - CITIC Securities highlighted the recent appreciation of the RMB, which benefits RMB-denominated equity assets, and indicated that the central bank's policy tools will be used more flexibly, focusing on domestic demand targets [11] - The outlook for 2026 suggests stable macro-financial conditions pointing to a stable banking operating environment, with expectations for bank interest margins to bottom out and income and profit recovery in the real sector [11]